ONC 201 - Oncoceutics

Drug Profile

ONC 201 - Oncoceutics

Alternative Names: NSC-350625; ONC201; ONC201 - Oncoceutics; TIC 10; TRAIL-inducing compound 10 (TIC10) - Oncoceutics

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncoceutics
  • Developer Case Comprehensive Cancer Center; Fox Chase Cancer Center; Oncoceutics; Rutgers; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Imidazoles; Pyrimidinones; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Extracellular signal-regulated MAP kinase inhibitors; Mitogen activated protein kinase 3 inhibitors; Proto oncogene protein c-akt inhibitors; Ras signal transduction pathway inhibitors; TRAIL receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometrial cancer; Glioblastoma; Neuroendocrine tumours
  • Phase I/II Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Phase I Solid tumours
  • Preclinical Breast cancer; Colorectal cancer; Mantle-cell lymphoma; Pancreatic cancer

Most Recent Events

  • 03 Oct 2017 Oncoceutics plans a phase II trial for Glioma in USA (NCT03295396)
  • 27 Sep 2017 Oncoceutics receives SBIR grant from National Institutes of Health for ONC 201 development in Endometrial cancer
  • 27 Sep 2017 Oncoceutics plans a phase II trial for Type II Endometrial cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top